Fractyl Health (GUTS) Research & Development (2023 - 2026)
Fractyl Health (GUTS) reported Research & Development of $15.6 million for Q1 2026, down 19.74% year-on-year from $19.4 million in Q1 2025, and down 5.43% quarter-over-quarter from $16.5 million in Q4 2025.
Fractyl Health (GUTS) has 4 years of Research & Development data on file, last reported at $15.6 million in Q1 2026.
- For the quarter ending Q1 2026, Research & Development fell 19.74% year-over-year to $15.6 million; the trailing twelve-month figure through Mar 2026 stood at $70.7 million (down 6.34% YoY), and the FY2025 full-year result was $74.5 million, up 5.77% from the prior year.
- Research & Development for Q1 2026 stood at $15.6 million, down from $16.5 million in the prior quarter.
- Across five years, Research & Development topped out at $21.2 million in Q2 2025 and bottomed at $9.1 million in Q2 2023.
- A 4-year average of $15.3 million and a median of $16.5 million in 2025 frame the typical range for Research & Development.
- Across the five-year window, Research & Development jumped 102.56% in 2024 and retreated 19.74% in 2026, its largest moves.
- Tracing GUTS's Research & Development over 4 years: stood at $10.2 million in 2023, then soared by 99.5% to $20.3 million in 2024, then slipped by 18.68% to $16.5 million in 2025, then dropped by 5.43% to $15.6 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $15.6 million, $16.5 million, and $17.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,638,563.89 Bn | 1,638,563.89 Bn | - | 626,092.00 |
| 2 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - | 4.32 Mn |
| 3 | Legend Biotech | 2,937.00 Bn | 2,936.10 Bn | 242.10 Mn | -101.30 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 2,169.69 Bn | 2,169.69 Bn | - | 1.46 Mn |
| 6 | Vertex Pharmaceuticals | 110.41 Bn | 103.16 Bn | 2.59 Bn | 961.60 Mn |
| 7 | Regeneron Pharmaceuticals | 66.44 Bn | 57.69 Bn | 3.31 Bn | 1.54 Bn |
| 8 | Evaxion A | 65.44 Bn | 65.42 Bn | - | -2.30 Mn |
| 9 | Alnylam Pharmaceuticals | 39.53 Bn | 36.52 Bn | 959.66 Mn | 364.87 Mn |
| 10 | Fractyl Health | 19.24 Mn | 19.24 Mn | - | 15.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15.60 Mn |
| Dec 31, 2025 | 16.49 Mn |
| Sep 30, 2025 | 17.46 Mn |
| Jun 30, 2025 | 21.15 Mn |
| Mar 31, 2025 | 19.44 Mn |
| Dec 31, 2024 | 20.28 Mn |
| Sep 30, 2024 | 19.00 Mn |
| Jun 30, 2024 | 16.76 Mn |
| Mar 31, 2024 | 14.42 Mn |
| Dec 31, 2023 | 10.17 Mn |
| Sep 30, 2023 | 9.38 Mn |
| Jun 30, 2023 | 9.14 Mn |
| Mar 31, 2023 | 9.35 Mn |